Preclinical studies have shown that the concurrent inhibition of IFN-γ and TNF-α signaling pathways can diminish the severity of PANoptosis-driven cytokine storms.[5,90,91] The JAK1-JAK2 inhibitor Baricitinib has demonstrated efficacy in reducing the recovery time for hospitalized COVID-19 patients.[92]. This evidence concerns the gene JAK2 and COVID-19.